Qube Research & Technologies LTD Blueprint Medicines Corp Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Qube Research & Technologies LTD holds 350,090 shares of BPMC stock, worth $28.9 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
350,090
Previous 276,344
26.69%
Holding current value
$28.9 Million
Previous $25.6 Million
19.51%
% of portfolio
0.04%
Previous 0.04%
Shares
9 transactions
Others Institutions Holding BPMC
# of Institutions
380Shares Held
61.5MCall Options Held
1.6MPut Options Held
1.41M-
Vanguard Group Inc Valley Forge, PA6.77MShares$559 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$549 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$469 Million0.06% of portfolio
-
State Street Corp Boston, MA2.5MShares$206 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.94MShares$160 Million0.44% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $4.93B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...